Showing 3761-3770 of 4164 results for "".
- Eversight Partners with LighTopTech to Improve Imaging Modalities for Eye Tissueshttps://modernod.com/news/eversight-partners-with-lightoptech-to-improve-imaging-modalities-for-eye-tissues/2482310/Eversight announced a 4-year partnership with LighTopTech that aims to improve imaging modalities for eye tissues in both clinical and research settings. Financial terms of the deal were not disclosed. As part of th
- Harrow Announces 52-Week Data from Vevye ESSENCE-2 Open-Label Extension Studyhttps://modernod.com/news/harrow-announces-52-week-data-from-vevye-essence-2-open-label-extension-study/2482309/Harrow has announced results from its ESSENCE‑2 open-label extension (OLE) clinical study for Vevye (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED). ESSENCE-2 OLE was a phase 3, prospective, multicent
- Drug Farm Gets Green Light from FDA to Initiate Phase 1b Trial of DF-003 in ROSAH Syndrome Patientshttps://modernod.com/news/drug-farm-gets-green-light-from-fda-to-initiate-phase-1b-trial-of-df-003-in-rosah-syndrome-patients/2482284/The FDA has cleared Drug Farm's investigational new drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1) inhibitor for clinical evaluation in ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache) synd
- EyePoint Fails to Reach Primary Efficacy Endpoint in Phase 2 Trial of Duravyu in NPDRhttps://modernod.com/news/eyepoint-fails-to-reach-primary-efficacy-endpoint-in-phase-2-trial-of-duravyu-in-npdr/2482265/EyePoint Pharmaceuticals announced topline results of its phase 2 PAVIA clinical trial evaluating Duravyu (vorolanib intravitreal insert), previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy (NPDR). In the trial, Duravyu did not meet the pre-specified p
- RetiSpec and Topcon Healthcare Announce Collaboration to Help Bring Eye-Based AI Diagnostic Tool to Markethttps://modernod.com/news/retispec-and-topcon-healthcare-announce-collaboration-to-help-bring-eye-based-ai-diagnostic-tool-to-market/2482256/Topcon Healthcare announced it has invested in RetiSpec and the two companies are collaborating to bring RetiSpec technology to market. The collaboration will bring neurology and eye care closer together. RetiSpec's clinically validated eye diagnostic AI aims to help healthcare
- Qlaris Bio Completes $24 Million Series B Financing Round to Advance IOP-lowering Drug Candidate for Glaucomahttps://modernod.com/news/qlaris-bio-completes-24-million-series-b-financing-round-to-advance-iop-lowering-drug-candidate-for-glaucoma/2482252/Qlaris Bio announced it has closed a $24 million Series B financing round to support the continued clinical development of QLS‑111, a first-in-class therapeutic being developed to lower IOP by targeting episcleral venous pressure (EVP). Qlaris is currently conducting two US ph
- Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating Aqueous Outflow Restorative Procedure with OMNIhttps://modernod.com/news/sight-sciences-announces-the-publication-of-large-scale-real-world-migs-study-demonstrating-aqueous-outflow-restorative-procedure-with-omni/2482226/Sight Sciences announced the results as published in the American Journal of Ophthalmology (AJO) International of a large scale, comparative real-world clinical outcomes study of patients treated by three leading, minimally invasive glaucoma surgery (MIGS) technologies.
- ViGeneron Announces First Patient Dosed in Phase 1b Trial of VG901 for the Intravitreal Treatment of RPhttps://modernod.com/news/vigeneron-announces-first-patient-dosed-in-phase-1b-trial-of-vg901-for-the-intravitreal-treatment-of-rp/2482224/ViGeneron announced that the first patient has been dosed in its phase Ib clinical trial evaluating intravitreal injection of VG901 to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. This milestone marks an important advance as the company continues to leverage it
- FDA Approves Ocugen's IND Amendment to Initiate Phase 3 Trial for RP Gene Therapyhttps://modernod.com/news/fda-approves-ocugens-ind-amendment-to-initiate-phase-3-trial-for-rp-gene-therapy/2482220/Ocugen announced that the FDA has cleared the company’s investigational new drug (IND) amendment to initiate a phase 3 clinical trial of OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). “The initiation of the OCU400 phase
- Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase 2 Trialshttps://modernod.com/news/qlaris-bios-novel-iop-lowering-product-qls111-is-dosed-in-phase-2-trials/2482195/Qlaris Bio announced the initiation and dosing of two separate US phase 2 masked, randomized clinical trials investigating QLS‑111 in patients with ocular hypertension and glaucoma. “The start of these phase 2 trials represents a key milestone in our goal of bringing QLS‑111